Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Background - Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have be...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 3, 2013
|
| In: |
The lancet. Oncology
Year: 2013, Volume: 14, Issue: 11, Pages: 1055-1066 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(13)70380-2 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(13)70380-2 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204513703802 
|
| Author Notes: | Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1787311201 | ||
| 003 | DE-627 | ||
| 005 | 20230428005736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220127s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(13)70380-2 |2 doi | |
| 035 | |a (DE-627)1787311201 | ||
| 035 | |a (DE-599)KXP1787311201 | ||
| 035 | |a (OCoLC)1341439139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a San-Miguel, Jesús F. |e VerfasserIn |0 (DE-588)143455028 |0 (DE-627)70449468X |0 (DE-576)337160635 |4 aut | |
| 245 | 1 | 0 | |a Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) |b a randomised, open-label, phase 3 trial |c Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos |
| 264 | 1 | |c September 3, 2013 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.01.2022 | ||
| 520 | |a Background - Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients. - Methods - This multicentre, open-label, randomised phase 3 trial was undertaken in Australia, Canada, Europe, Russia, and the USA. Patients were eligible if they had been diagnosed with refractory or relapsed and refractory multiple myeloma, and had failed at least two previous treatments of bortezomib and lenalidomide. They were assigned in a 2:1 ratio with a validated interactive voice and internet response system to either 28 day cycles of pomalidomide (4 mg/day on days 1-21, orally) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally) or high-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20, orally) until disease progression or unacceptable toxicity. Stratification factors were age (≤75 years vs >75 years), disease population (refractory vs relapsed and refractory vs bortezomib intolerant), and number of previous treatments (two vs more than two). The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01311687, and with EudraCT, number 2010-019820-30. - Findings - The accrual for the study has been completed and the analyses are presented. 302 patients were randomly assigned to receive pomalidomide plus low-dose dexamethasone and 153 high-dose dexamethasone. After a median follow-up of 10·0 months (IQR 7·2-13·2), median PFS with pomalidomide plus low-dose dexamethasone was 4·0 months (95% CI 3·6-4·7) versus 1·9 months (1·9-2·2) with high-dose dexamethasone (hazard ratio 0·48 [95% CI 0·39-0·60]; p<0·0001). The most common grade 3-4 haematological adverse events in the pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups were neutropenia (143 [48%] of 300 vs 24 [16%] of 150, respectively), anaemia (99 [33%] vs 55 [37%], respectively), and thrombocytopenia (67 [22%] vs 39 [26%], respectively). Grade 3-4 non-haematological adverse events in the pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups included pneumonia (38 [13%] vs 12 [8%], respectively), bone pain (21 [7%] vs seven [5%], respectively), and fatigue (16 [5%] vs nine [6%], respectively). There were 11 (4%) treatment-related adverse events leading to death in the pomalidomide plus low-dose dexamethasone group and seven (5%) in the high-dose dexamethasone group. - Interpretation - Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients with refractory or relapsed and refractory multiple myeloma. - Funding - Celgene Corporation. | ||
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lacy, Martha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Song, Kevin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delforge, Michel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Karlin, Lionel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Banos, Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oriol, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Alegre, Adrian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chen, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cavo, Michele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garderet, Laurent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ivanova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martinez-Lopez, Joaquin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Belch, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Palumbo, Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schey, Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yu, Xin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sternas, Lars |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacques, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaki, Mohamed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 14(2013), 11 vom: Okt., Seite 1055-1066 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) a randomised, open-label, phase 3 trial |
| 773 | 1 | 8 | |g volume:14 |g year:2013 |g number:11 |g month:10 |g pages:1055-1066 |g extent:12 |a Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) a randomised, open-label, phase 3 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(13)70380-2 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1470204513703802 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220127 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1787311201 |e 4045699171 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Jesús F.","role":"aut","display":"San-Miguel, Jesús F.","family":"San-Miguel"},{"given":"Katja","role":"aut","family":"Weisel","display":"Weisel, Katja"},{"family":"Moreau","display":"Moreau, Philippe","given":"Philippe","role":"aut"},{"role":"aut","given":"Martha","family":"Lacy","display":"Lacy, Martha"},{"given":"Kevin","role":"aut","family":"Song","display":"Song, Kevin"},{"role":"aut","given":"Michel","display":"Delforge, Michel","family":"Delforge"},{"role":"aut","given":"Lionel","family":"Karlin","display":"Karlin, Lionel"},{"given":"Hartmut","role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"given":"Anne","role":"aut","family":"Banos","display":"Banos, Anne"},{"role":"aut","given":"Albert","family":"Oriol","display":"Oriol, Albert"},{"given":"Adrian","role":"aut","family":"Alegre","display":"Alegre, Adrian"},{"role":"aut","given":"Christine","family":"Chen","display":"Chen, Christine"},{"family":"Cavo","display":"Cavo, Michele","role":"aut","given":"Michele"},{"family":"Garderet","display":"Garderet, Laurent","given":"Laurent","role":"aut"},{"family":"Ivanova","display":"Ivanova, Valentina","given":"Valentina","role":"aut"},{"given":"Joaquin","role":"aut","family":"Martinez-Lopez","display":"Martinez-Lopez, Joaquin"},{"display":"Belch, Andrew","family":"Belch","role":"aut","given":"Andrew"},{"display":"Palumbo, Antonio","family":"Palumbo","given":"Antonio","role":"aut"},{"family":"Schey","display":"Schey, Stephen","given":"Stephen","role":"aut"},{"display":"Sonneveld, Pieter","family":"Sonneveld","given":"Pieter","role":"aut"},{"family":"Yu","display":"Yu, Xin","role":"aut","given":"Xin"},{"family":"Sternas","display":"Sternas, Lars","given":"Lars","role":"aut"},{"family":"Jacques","display":"Jacques, Christian","given":"Christian","role":"aut"},{"family":"Zaki","display":"Zaki, Mohamed","given":"Mohamed","role":"aut"},{"role":"aut","given":"Meletios","display":"Dimopoulos, Meletios","family":"Dimopoulos"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003)","title_sort":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003)","subtitle":"a randomised, open-label, phase 3 trial"}],"note":["Gesehen am 27.01.2022"],"origin":[{"dateIssuedDisp":"September 3, 2013","dateIssuedKey":"2013"}],"id":{"eki":["1787311201"],"doi":["10.1016/S1470-2045(13)70380-2"]},"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos"]},"relHost":[{"titleAlt":[{"title":"The lancet <London> / Oncology"}],"part":{"pages":"1055-1066","year":"2013","issue":"11","text":"14(2013), 11 vom: Okt., Seite 1055-1066","volume":"14","extent":"12"},"language":["eng"],"id":{"issn":["1474-5488"],"zdb":["2035574-9"],"eki":["325349770"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"325349770","disp":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) a randomised, open-label, phase 3 trialThe lancet. Oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group","dateIssuedKey":"2000","publisherPlace":"London"}],"pubHistory":["0.2000 -"],"note":["Gesehen am 22.09.2021"],"title":[{"title":"The lancet","title_sort":"lancet","partname":"Oncology"}]}],"recId":"1787311201"} | ||
| SRT | |a SANMIGUELJPOMALIDOMI3201 | ||